These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 15049280)

  • 1. [Treatment of pulmonary arterial hypertension associated to systemic sclerosis].
    Hachulla E
    Rev Med Interne; 2004 Mar; 25(3):195-200. PubMed ID: 15049280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
    Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M
    Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pulmonary arterial hypertension and systemic sclerosis].
    Launay D; Humbert M; Hachulla E
    Presse Med; 2006 Dec; 35(12 Pt 2):1929-37. PubMed ID: 17159719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
    Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D
    Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.
    McLaughlin VV
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():10-5. PubMed ID: 16919005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
    Kabunga P; Coghlan G
    Drugs; 2008; 68(12):1635-45. PubMed ID: 18681488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis.
    McLaughlin V; Humbert M; Coghlan G; Nash P; Steen V
    Rheumatology (Oxford); 2009 Jun; 48 Suppl 3():iii25-31. PubMed ID: 19487219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current treatment options in children with pulmonary arterial hypertension and experiences with oral bosentan.
    Beghetti M
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():16-24. PubMed ID: 16919006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
    Denton CP; Humbert M; Rubin L; Black CM
    Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy.
    Seyfarth HJ; Pankau H; Hammerschmidt S; Schauer J; Wirtz H; Winkler J
    Chest; 2005 Aug; 128(2):709-13. PubMed ID: 16100158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan.
    Rotondo C; Praino E; Nivuori M; di Serio F; Lapadula G; Iannone F
    Int J Rheum Dis; 2017 Jan; 20(1):90-96. PubMed ID: 26218502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of iloprost and bosentan in pulmonary arterial hypertension.
    Saleh JA
    Niger J Med; 2008; 17(1):13-9. PubMed ID: 18390125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids.
    Hoeper MM; Taha N; Bekjarova A; Gatzke R; Spiekerkoetter E
    Eur Respir J; 2003 Aug; 22(2):330-4. PubMed ID: 12952269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival in systemic sclerosis with pulmonary arterial hypertension has not improved in the modern era.
    Rubenfire M; Huffman MD; Krishnan S; Seibold JR; Schiopu E; McLaughlin VV
    Chest; 2013 Oct; 144(4):1282-1290. PubMed ID: 23744060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment with bosentan for pulmonary hypertension and reduced peripheral circulation in juvenile systemic sclerosis.
    Shimizu M; Hashida Y; Ueno K; Yokoyama T; Nakayama Y; Saito T; Ohta K; Takehara K; Yachie A
    Pediatr Cardiol; 2011 Oct; 32(7):1040-2. PubMed ID: 21789477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The treatment of idiopathic pulmonary artery hypertension and its relation to systemic scleroderma].
    Humbert M
    Rev Med Interne; 2007 Dec; 28 Suppl 4():S273-6. PubMed ID: 17961866
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
    Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
    J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bosentan: a review of its use in pulmonary arterial hypertension and systemic sclerosis.
    Oldfield V; Lyseng-Williamson KA
    Am J Cardiovasc Drugs; 2006; 6(3):189-208. PubMed ID: 16780392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low occurrence of digital ulcers in scleroderma patients treated with bosentan for pulmonary arterial hypertension: a retrospective case-control study.
    Cozzi F; Pigatto E; Rizzo M; Favaro M; Zanatta E; Cardarelli S; Riato L; Punzi L
    Clin Rheumatol; 2013 May; 32(5):679-83. PubMed ID: 23344686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?
    Steele P; Strange G; Wlodarczyk J; Dalton B; Stewart S; Gabbay E; Keogh A
    BMC Cardiovasc Disord; 2010 Feb; 10():9. PubMed ID: 20170553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.